June 13, 2016
Cambridge, MA

Multiple Charities Join Solid to Defeat Duchenne muscular dystrophy

Solid is proud to announce that three leading charities from around the world, Duchenne Now, Save Our Sons and Fight DMD, have joined our fight to solve Duchenne muscular dystrophy (DMD) and improve the lives of patients.  The generous grants provided by these organizations will directly fund our research programs to find new breakthroughs in DMD treatment. 

The grants include:

Duchenne Now: The U.K.-based organization founded by Tony Levene, Vici Richardson and Paul Fitzpatrick has committed a one-time grant of $150,000 to fund our Disease Modifying Therapy programs targeted at managing the symptoms associated with disease progression.

Fight DMD: Founded by Terry Marlin in Tennessee USA, the organization has committed $100,000 dollars over two years to fund efforts within our Solid GT program to identify next generation technologies that may restore dystrophin protein expression in the body.

Save Our Sons: The Australian organization founded by Elie Eid has committed $400,000 Australian Dollars over two years to fund different efforts within our Disease Modifying Therapy and Solid GT programs, including the development of potential symptomatic therapies, certain aspects of our AAV-associated micro-dystrophin gene therapy program and our ongoing efforts to uncover new technologies that may restore dystrophin expression.

“I want to give special thanks to each of the children for which these charities were formed – Emilio, Joey, Josh, Zak, Raul, Jonah and Emory,” said Annie Ganot, head of Patient Advocacy at Solid Biosciences.  “It is you and your families who inspire us every day in our work to develop treatments for all boys and young men with Duchenne muscular dystrophy.”

This is the first time that Duchenne Now, Save Our Sons and Fight DMD have contributed grants to Solid Biosciences.  As part of our commitment to partnership and transparent communication, Solid will provide each organization with regular updates to show our work and progress.

If you are a charity and would like to partner with Solid on ongoing projects,

Click Here

Related news


The Duchenne Research Fund (DRF) provided Solid with a research grant of $600,000 to support its LTBP4 program to combat fibrosis and to support novel biomarker work in Duchenne muscular dystrophy (DMD).


It has been an exciting and emotional time for our Duchenne muscular dystrophy (DMD) community.


Solid Biosciences congratulates Sarepta on the U.S. approval of the first therapy for Duchenne muscular dystrophy.


Solid was proud to sponsor the 8th Annual Gals For Cal team at the recent Max Performance Title 9 Triathlon at Hopkinton State Park in Massachusetts.


Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.


Solid Biosciences Community Update Q2 2016


The biologic candidate LTBP4 has the potential to promote muscle health and reduce fibrosis in patients with Duchenne muscular dystrophy.


Carl Morris, Solid Biosciences’ vice president of Research and Development, speaks about being a “Game Changer in Rare Disease.”


More information about Solid?

Please subscribe to receive our latest news